decitabine
Drug20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
Other names: Dacogen
NCT Number: NCT00358644
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Phase 2
Duarte, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
Other names: Dacogen
Time frame: 1 year
Eisai Inc.
Industry
A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03836209
Acute Myeloid Leukemia, Hematologic Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT03374332
Acute Myeloid Leukemia, Disease Attributes
Providence, Rhode Island, United States
View Trial DetailsNCT03455504
Acute Myeloid Leukemia, Hematologic Diseases
Bergamo, Italy
View Trial DetailsNCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial Details